NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE
Clinical trials for NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE explained in plain language.
Never miss a new study
Get alerted when new NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE trials appear
Sign up with your email to follow new studies for NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for rare, aggressive blood cancer
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy can help people with a rare and aggressive type of lymphoma (NK/T-cell lymphoma) that has spread. About 84 newly diagnosed patients will be randomly assigned to receive either the combinati…
Matched conditions: NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New trial aims to find best treatment order for rare lymphoma
Disease control Recruiting nowThis study compares three different sequences of chemotherapy and radiation for people with early-stage natural killer/T-cell lymphoma, a rare and aggressive cancer. About 210 participants will be randomly assigned to one of three treatment plans. The goal is to see which approac…
Matched conditions: NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC